MedPath

Mucosta trial (Mucosta trial)

Recruiting
Conditions
Patients with dry eye complicated by Sjogren's syndrome
Registration Number
jRCT1031220298
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
20
Inclusion Criteria

Patients who meet all of the following criteria will be considered (1) Written consent has been obtained from the patient or a surrogate (2) Men and women who are at least 18 years of age at the time of consent acquisition. (3) Patient must have a diagnosis of Sjogren's syndrome based on the revised diagnostic criteria of the Ministry of Health in 1999. (4) Patient has a diagnosis of dry eye based on the revised dry eye practice guideline criteria by the 2019 Dry Eye Study Group Practice Guideline Development Committee.

Exclusion Criteria

Patients who meet all of the following criteria will be considered. (1) Patients with active inflammatory ocular or eyelid disease. (2) Patients with eyelid closure defects. (3) Patients with a history of graft-versus-host disease. (4) Other persons deemed by the principal investigator or subinvestigator to be inappropriate for the safe conduct of this study.

Study & Design

Study Type
Interventional
Study Design
parallel assignment
Primary Outcome Measures
NameTimeMethod
Change in fluorescein staining scoreDay 1 to Week 12

Change in fluorescein staining score (van Bijsterfeld method) from the start of treatment (Day 1) to Week 12

Secondary Outcome Measures
NameTimeMethod
Dry Eye related Quality of life ScoreDay 1 to Weeks 4 and 12

The following changes from the start of treatment (Day 1) to Weeks 4 and 12

Tear film break-up timeDay 1 to Weeks 4 and 12

The following changes from the start of treatment (Day 1) to Weeks 4 and 12

Tear meniscusDay 1 to Weeks 4 and 12

The following changes from the start of treatment (Day 1) to Weeks 4 and 12

Schirmer testDay 1 to Weeks 4 and 12

The following changes from the start of treatment (Day 1) to Weeks 4 and 12

Change in fluorescein staining score (FCS)Day 1 to Weeks 4 and 12

The following changes from the start of treatment (Day 1) to Weeks 4 and 12

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.